Cometriq cabozantinib: Completed Phase III enrollment

Exelixis completed enrollment of 650 patients who progressed after =1 VEGF receptor tyrosine kinase inhibitor in the open-label, international Phase III METEOR trial comparing 60 mg oral Cometriq once...